Subscribe to receive this daily commentary directly in your email
Independent macro and options research, published every trading day — $85/mo or $750/yr
Subscribe →11.4.20
STOCKS – ACAD, BIIB
MACRO – SPY
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN ACAD
Mike’s Reading The Markets (RTM) Premium Content – NOW WITH A 2 WEEK FREE TRIAL
How ’bout them pollsters… I told you the race would be closer than the polls showed and that Trump had a good chance of winning. I thought he might even win. But I had no idea it would be this tight. I have no idea who will win at this point; I want this whole year to be done with—the market, the pandemic, and now this mess of an election. You’d think in the year 2020, in the most advanced country in the world, we would have better systems to track and count votes. Anyway…”
Stocks jumped as the volality imploded, and the Bluewave sweep (the balance of it) trade melted. The result was a massive shift into the technology sector.
From a technical standpoint, there are a lot of gaps down below that need to be filled. I guess is that after today, and investors have some time to reflect, they may find themselves feeling differently about today’s big gains.
Again, I think most of today’s rally had to more with the mechanics of the market and the unwind of the volality, then anything. Navigating The Market · By Michael Kramer Independent macro and options research, published every trading day. Daily written analysis covering gamma exposure, dealer flows, key levels, and the macro drivers moving markets. Includes full video access. Recent Subscriber Analysis
Biogen (BIIB)
Biogen was the stock of the day, jumping by over 40% ahead of its ADCOM meeting for aducanumab’s potential approval for Alzheimer’s. This stock hasn’t done anything for years. The chart tells you nothing, but you can see how broken up the trading has been.
The Market Chronicles · Video Membership The daily market commentary, delivered in video. Same daily market analysis, in video form — available to YouTube channel members only. Latest Videos
Acadia (ACAD)
Acadia reported results after the close with revenue that came in better than expected. I haven’t looked too closely at the results, I saw they missed earnings estimates. This isn’t about the top and bottom-line results for them at this point. What will drive this stock will be a Nuplazid’s potential in Dementia-Related Psychosis and hopefully getting approval from the FDA by the beginning of April.
That’s all for today.
Mike
Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and, unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future results.
This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.
Bill Flows Set To Flip As Dispersion Compresses Into QRA Week
Mott Capital's Market Chronicles 3 hours ago